brimonidine tartrate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
brimonidine tartrate: clinical details
Prescribing considerations
- Confirm the intended formulation because ophthalmic and cutaneous products have different indications, administration and safety profiles.
- For eye drops, consider cardiovascular disease, orthostatic hypotension, coronary or cerebral insufficiency, Raynaud's phenomenon, depression, dry eye, corneal compromise and hepatic or renal impairment.
- For gel, assess cardiovascular stability and avoid damaged or irritated skin because systemic absorption may increase.
- Eye drops are contraindicated below 2 years and not recommended below 12 years; gel should not be used below 18 years.
- Counsel about delayed ocular hypersensitivity and rosacea exacerbation or rebound redness.
Contraindications and cautions
- Hypersensitivity to brimonidine or formulation excipients.
- Neonates and infants younger than 2 years.
- Monoamine oxidase inhibitors or antidepressants affecting noradrenergic transmission, including relevant tricyclic or tetracyclic agents.
- The gel is not for paediatric rosacea treatment.
Monitoring
- For eye drops, monitor intraocular pressure, response, ocular allergy, corneal surface and tolerability.
- Review new drowsiness, fatigue, dizziness, syncope, hypotension or heart-rate disturbance.
- For gel, review worsening erythema, flushing or burning and any cardiovascular symptoms.
- Use close observation if ophthalmic brimonidine is exceptionally used in an older child.
Clinical pharmacology
Brimonidine is a highly selective alpha-2 adrenergic agonist. Ophthalmic action combines reduced aqueous-humour formation with increased uveoscleral outflow; cutaneous action is direct vasoconstriction of superficial facial vessels. Systemic exposure is generally low after topical use, but important central or cardiovascular effects can occur.
Formulation and product differences
- Eye drops contain benzalkonium chloride, which can irritate the ocular surface and discolour soft contact lenses.
- Facial gel contains propylene glycol, which may irritate skin, and methylparahydroxybenzoate, which may cause allergic reactions.
- Eye drops reduce ocular pressure; gel treats adult facial erythema of rosacea and must not be used in or near the eyes.
brimonidine tartrate preparations and strengths
Gel
Route: Cutaneous
Strengths: 3 mg/g
Eye drops
Route: Ophthalmic
Strengths: 2 mg/mL, 0.2% w/v
brimonidine tartrate interactions
Tell the prescriber about all medicines, including eye drops, skin treatments and non-prescription products.
Monoamine oxidase inhibitors
Concomitant use is contraindicated because noradrenergic effects may be altered or increased.
Tricyclic or tetracyclic antidepressants and mianserin
Medicines affecting noradrenergic transmission are contraindicated with the selected products.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.